RAMP3 is a prognostic indicator of liver cancer and might reduce the adverse effect of TP53 mutation on survival. (8th June 2018)

• Record Type: Journal Article
• Authors: Fang, Aiping; Zhou, Shijie; Su, Xiaolan; Liu, Chuang; Chen, Xiaoxin; Wan, Yang; Lei, Xiaohong; Xie, Linshen; Jia, Yiping; Wang, Wenzhi; Yang, Luo; Song, Xuejiao; Yao, Yuqin
• Is Part Of: Future oncology. Volume 14:Number 25(2018)
• Page Start: 2615
• Page End: 2625
• Publication Date: 2018-06-08
• Subjects: hepatocellular carcinoma -- overall survival -- RAMP3 -- recurrence-free survival; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0296
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To assess the prognostic value of RAMP3 expression in terms of overall survival (OS) and recurrence-free survival (RFS) in hepatocellular carcinoma (HCC) patients.Materials & methods: Immunochemistry staining was performed to detect RAMP3 expression. Data in the Cancer Genome Atlas-Liver Hepatocellular Cancer were used for secondary analysis.Results: RAMP3 expression was significantly downregulated in HCC tissues than in normal liver tissues. Increased RAMP3 expression was an independent prognostic factor of favorable OS (hazard ratio [HR]: 0.772, 95% CI: 0.689–0.864; p < 0.001) and RFS (HR = 0.719, 95% CI: 0.633–0.817; p < 0.001). High RAMP3 expression was associated with significantly better RFS in both TP53 mutant and wildtype groups.Conclusion: High RAMP3 RNA expression is an independent prognostic factor of favorable OS and RFS in patients with HCC.